MyBlueDotsMeiji Seika Pharma Invests in MPM BioImpact’s New Technologies and Virology Strategy MyBlueDots2 months ago01 mins TOKYO–(BUSINESS WIRE)–Meiji Seika Pharma invests in MPM BioImpact’s new technology and virology strategy to expand early-stage opportunities and enhance the global network. Go to Source Author: Post navigation Previous: Amylyx Pharmaceuticals Announces Proposed Public Offering of Common StockNext: Yagi & Co., Ltd.: New Material “LAVATECH” Containing Lava from Mt. Fuji to Be Exhibited at Heimtextil 2025
Some animals’ natural biological defenses could inspire new approaches to cancer prevention and treatment in humans MyBlueDots2 days ago 0
‘Overlooked’ scrub typhus may affect 1 in 10 in rural India and be a leading cause of hospitalizations for fever MyBlueDots2 days ago 0